ReviewAllergy, asthma & immunology research2016
Guideline of Chronic Urticaria Beyond.
Review in Allergy, asthma & immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Management of chronic urticaria in children: a clinical guideline.Italian journal of pediatrics · 2019Guideline
- Effect of combining histaglobulin with antihistamines in patients with chronic spontaneous urticaria in a tertiary care hospital setting- a randomized trial.Archives of dermatological research · 2025Trial
- Elucidating the Mechanism of Xiaoqinglong Decoction in Chronic Urticaria Treatment: An Integrated Approach of Network Pharmacology, Bioinformatics Analysis, Molecular Docking, and Molecular Dynamics Simulations.Current computer-aided drug design · 2026Article
- Article
- A single-dose, randomized, open-label, four-period, crossover equivalence trial comparing the clinical similarity of the proposed biosimilar rupatadine fumarate to reference WystammFrontiers in pharmacology · 2024Article
- The role of gut microbiome in inflammatory skin disorders: A systematic review.Dermatology reports · 2022Article
- High-dose non-sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab.Clinical and translational allergy · 2021Article
- Review
- The efficacy and safety of herbal combination of Unani Medicine in chronic urticaria: A randomized, controlled study.Journal of traditional and complementary medicine · 2021Article
- The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations.The World Allergy Organization journal · 2021Review
- Gut Microbiome and Serum Metabolome Analyses Identify Unsaturated Fatty Acids and Butanoate Metabolism Induced by Gut Microbiota in Patients With Chronic Spontaneous Urticaria.Frontiers in cellular and infection microbiology · 2020Article
- Risk of Urticaria in Children with Type 1 Diabetes Mellitus: A Nationwide Cohort Study.International journal of environmental research and public health · 2019Article
- Emerging Therapies in Chronic Spontaneous Urticaria.Allergy, asthma & immunology research · 2019Review
- Chronic urticaria and drug hypersensitivity in children.Acta bio-medica : Atenei Parmensis · 2019Review
- Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.Journal of managed care & specialty pharmacy · 2018Observational
- Urticaria and Angioedema: an Update on Classification and Pathogenesis.Clinical reviews in allergy & immunology · 2018Review
- The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.Frontiers in pharmacology · 2018Article
- Etiology of chronic urticaria: the Ecuadorian experience.The World Allergy Organization journal · 2018Article
- Clinical Course of Chronic Spontaneous Urticaria in the Korean Adult Population.Allergy, asthma & immunology research · 2018Article
- Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014.Allergy, asthma & immunology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urticaria is a relatively common condition that if chronic can persist for weeks, months or years and affect quality of life significantly. The etiology is often difficult to determine, especially as it becomes chronic. Many cases of chronic urticaria are thought to be autoimmune, although there is no consensus that testing for autoimmunity alters the diagnostic or management strategies or outcomes. Many times, urticaria is easily managed with antihistamines and/or short courses of oral corticosteroids, but too often control is insufficient and additional therapies must be added. For years, immune modulating medications, such as cyclosporine and Mycophenolate Mofetil, have been used in cases refractory to antihistamines and oral corticosteroids, although the evidence supporting their efficacy and safety has been limited. Omalizumab was recently approved for the treatment of chronic urticaria unresponsive to H1-antagonists. This IgG anti-IgE monoclonal antibody has been well demonstrated to safely and effectively control chronic urticaria at least partially in approximately 2/3 of cases. However, the mechanism of action and duration of treatment for omalizumab is still unclear. It is hoped that as the pathobiology of chronic urticaria becomes better defined, future therapies that target specific mechanistic pathways will be developed that continue to improve the management of these often challenging patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.